weight regain after stopping glp-1 agonists Trajectory of the body drug discontinuation in the treatment of anti-obesity medications | BMC Medicine Efficacy of the Glucagon-Like Peptide-1
Description
Following the success and approval of tirzepatide (Mounjaro, Eli Lilly, Indianapolis, IN, USA) in 2022 by FDA for treatment of T2DM, the SURMOUNT programme investigated its use as an anti-obesity medication in those without diabetes
J.YanchunasJ.WeigeltC.KishK.KleiH
A sensitivity analysis excluding the ITCA trial yielded a similar point estimate, although statistical significance was not retained (HR (95%CI): 0.87 (0.751.01)
McMaster University and Evidence Prime
